A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
Clinical trial NCT06542250 · RECRUITING
Trial details
- NCT number
- NCT06542250
- Sponsor
- AstraZeneca
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-09-18
- Primary completion
- 2029-12-18
- Enrollment
- 174
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.